Sanofi: FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation For Hemophilia A

French drug major Sanofi (SNYNF, SNY) announced Wednesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A.